Rhapsido (Remibrutinib) for Chronic Spontaneous Urticaria: Phase 3 Efficacy Data
Is there finally a fast-acting oral treatment for chronic hives? In this episode of the Science of Skin Podcast, board-certified dermatologist Dr. Ted Lain is joined by Dr. Naiem Issa, a dermatologist in Northern Virginia and assistant professor of dermatology at the University of Miami and George Washington University, to break down the phase 3 clinical trial results for Rhapsido (remibrutinib), the first oral BTK inhibitor for chronic spontaneous urticaria (CSU).
Dr. Issa explains how Bruton's tyrosine kinase (BTK) inhibition works inside the mast cell to block the signals that lead to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.